Revenues rise for AMPAC

AMPAC reported a 55% increase in fine chemicals segment revenues to $21.5m in its Q1 2012. Dana Kelley, AMPAC vice-president, CFO and treasurer, said that revenues from antiviral products were the primary contributor to the rise as the 2012 first quarter included no antiviral product revenue. Joe Carleone, AMPAC president and CEO, said the company had recently agreed to produce controlled substances for a large pharmaceutical customer and will soon be conducting a full scale validation of a chemical product in this area.
Seeking Alpha